{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:48Z","timestamp":1777934628258,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Drug\u2013drug interactions (DDIs) occur when one drug interferes with the pharmacological activity of another and can lead to increased side effects. The purpose of this study was to examine potential interactions between antimicrobials and other drugs in patients with hematological malignancies (HMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      The medications used by 233 patients with HMs before and during hospitalization in Ankara City Hospital Hematology Clinic services between January 2021 and July 2021 were examined. Potential DDIs (pDDIs) were identified through UptoDate, Drugs.com, and MedScape databases. The effects of major antimicrobial-related pDDIs on patients were examined. Agreement between the two interaction systems was judged based on the kappa test. SPSS R Version 4.0.2 was used in the statistical analysis of the data,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.05 was considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The prevalence of polypharmacy before hospitalization was determined as 22.7%. Diagnosed with acute leukemia and multiple myeloma, more antimicrobial-related pDDIs were detected during hospitalization (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.001). A total of 758 antimicrobial-related pDDIs, which were in the major category in at least one of the three databases, were detected in 72.5% (169\/233) of the participants. It was determined that the total hospitalization period of patients with major antimicrobial-related pDDIs was longer (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.001). There was negligible agreement between UptoDate and Dugs.com and between Drugs.com and MedScape (kappa: 0.008 for both). There was no compatibility between UptoDate and MedScape (kappa&lt;0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Interactions between antimicrobials and other drugs are undesirable problems. Further studies are required to evaluate the clinical and economic effects of the interactions on patients with HMs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241249419","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T03:34:02Z","timestamp":1714102442000},"page":"587-596","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of polypharmacy, antimicrobial-related potential drug\u2013drug interactions in patients with hematological malignancies"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7186-7670","authenticated-orcid":false,"given":"Zeynep","family":"Oktay","sequence":"first","affiliation":[{"name":"Ankara City Hospital, Department of Infection Disease and Clinical Microbiology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahmet","family":"G\u00fcner","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Infection Disease and Clinical Microbiology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bircan","family":"Kayaaslan","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Infection Disease and Clinical Microbiology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130mran","family":"Hasano\u011flu","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Infection Disease and Clinical Microbiology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Kaya Kalem","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Infection Disease and Clinical Microbiology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcls\u00fcm","family":"\u00d6zet","sequence":"additional","affiliation":[{"name":"Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Hematology, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-018-0478-3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Nucci M Anaissie EJ. Prevention of infections in patients with hematological malignancies. In: Wiernik P Dutcher J and Gertz M (eds) Neoplastic Diseases of the Blood 6th ed. Springer 2018.","DOI":"10.1007\/978-3-319-64263-5_49"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.438"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.07.015"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11657"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_8_2","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0. Cancer Ther Eval Progr. 2017;155 www.upen.terengganu.gov.my\/index.php\/2017 (accessed 23 July 2022)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"e_1_3_3_10_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology www.whocc.noatc_ddd_index (2023 accessed 5 January 2023)."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2004-164"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00844-3"},{"key":"e_1_3_3_13_2","first-page":"17","article-title":"Polypharmacy and drug interactions in elderly patients","volume":"45","author":"Y\u0131ld\u0131r\u0131m AB","year":"2017","unstructured":"Y\u0131ld\u0131r\u0131m AB, K\u0131l\u0131n\u00e7 AY. Polypharmacy and drug interactions in elderly patients. Turk Kardiyol Dern Ars 2017; 45: 17\u201321.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir492"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.11.014"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0998-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk130"},{"key":"e_1_3_3_18_2","first-page":"171","article-title":"Potential of drug interactions among hospitalized cancer patients in a developing country","volume":"12","author":"Tavakoli-Ardakani M","year":"2013","unstructured":"Tavakoli-Ardakani M, Kazemian K, Salamzadeh J, et al. Potential of drug interactions among hospitalized cancer patients in a developing country. Iran J Pharm Res 2013; 12: 171\u2013178.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2162-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-011-9574-2"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/jrptps.JRPTPS_67_18"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216664201"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1786-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-008-9191-x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2232-4"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241249419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241249419","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241249419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:47Z","timestamp":1777688987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241249419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10781552241249419"],"URL":"https:\/\/doi.org\/10.1177\/10781552241249419","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}